Building on our previous longitudinal analysis, which examined the role of novel tumor-infiltrating T cell clonotypes in reinvigorating antitumor responses following PD-1 blockade in advanced cutaneous basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (SCC) (7), we performed long-term clinical outcome monitoring, single cell transcriptome and immunoreceptor sequencing, and high-definition spatial transcriptomics of tumors and draining lymph node specimens collected over years of direct patient care. This evidence concerns the gene PDCD1 and neoplasm.